Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

CategoryBioTech
Employees
Founded2011

Offices

Southport, USA
167 Old Post Road
Southport, CT, 06890
USA

Funding

TOTAL $7.41M
FUNDING TOTAL $7.41M
Seed, 8/2011
Stonehenge Capital
Connecticut Innovations
$1.74M
Partial Close, 12/2012
$5.67M

Tags

Thetis Pharmaceuticals

Thetis Pharmaceuticals LLC is a bio-pharmaceutical company creating innovative chemistry and regulatory strategies in the development of prescription drugs in the Omega-3 arena.

The Company has three differentiated and IP-protected drug candidates at varying stages of development: TP-101 for the treatment of type 2 diabetes, TP-943 for the treatment of hypertriglyceridemia and mixed dyslipidemia, and TP-721 for the prevention and treatment of atrial fibrillation.

The key innovation underlying Thetis’ drug portfolio revolves around pharmaceuticalizing Omega-3 poly- unsaturated fatty acids into solid, water-soluble, new chemical entities (NCEs). This technology creates NCEs that instantaneously dissociate in aqueous media to deliver known entities in either a superior or targeted manner. Since the delivered entities are known drugs with excellent safety profiles, the Company expects to bypass many pre-clinical and clinical safety requirements and seek expedited registration in the U.S. Furthermore these novel chemical compounds have excellent prospects for superiority over existing Omega-3 drugs.

Recent Milestones

Videos

Screenshots

Sources

  1. Connecticut's Thetis Pharmaceuticals gains $1.5M seed investment (masshightech.com) [edit]
  2. SEC (sec.gov) [edit]
Edit This Page
Last Edited 10/23/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy